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Abstract 
3-Amino-substituted 5-aminopyrazoles were found to be suitable substrates for the 
synthesis of new 4-aminopyrazolo[1,5-a][1,3,5]triazines (5-aza-9-deaza-adenines) when 
used in the one-pot, three-component reaction with cyanamide and triethyl orthoformate 
under microwave irradiation. The reaction proceeded selectively and its scope was 
demonstrated by the preparation of a library of 4-aminopyrazolo[1,5-a][1,3,5]triazines. 
Some structural aspects of the prepared compounds were investigated using dynamic NMR 
spectroscopy and X-ray crystallography. The operational simplicity, short reaction time, and 
good reproducibility are attractive features of the developed robust and practical approach 
for the synthesis of 7-amino-substituted 4-aminopyrazolo[1,5-a][1,3,5]triazines.  
 
§ Part 34 in the series “Fused heterocyclic systems with an s-triazine ring.” For part 33 see 
ref.1  
2 
 
1. Introduction 
The ubiquitous presence of compounds with the purine scaffold in nature and their 
regulatory role in many biological processes2 inspired work on the development of new 
bioactive compounds resembling the structures of natural purines. Applied to the 1,3,5-
triazine based purine analogues,3 this strategy has been successfully implemented with the 
5-aza-9-deazapurine (pyrazolo[1,5-a][1,3,5]triazine) skeleton.4 Compounds with this scaffold 
often exhibit superior biological activity compared to their purine counterpart. For example, 
the replacement of purine scaffold with the 5-aza-9-deazapurine improved inhibitory 
activity5,6 and the increased affinity to the enzyme7 for cyclin-dependent kinase inhibitors 
designed as cancer therapeutics. A similar strategy was reported8 for the development of a 
Cav2 voltage gated calcium channel agonist with the 5-aza-9-deazapurine skeleton. It was 
significantly more effective than its purine analogue. 
In our program on the development of efficient methods for the preparation of new 
pyrazolo[1,5-a][1,3,5]triazines,9 we recently reported a microwave-assisted approach for 
the synthesis of novel 4-aminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylates 1.9a Later we 
found that some of these compounds exhibited promising biological activities (Fig. 1). For 
example, compounds 1a-d effectively inhibited the Trypanosoma cruzi growth with 
selectivity for myocardiocyte parasites (Fig 1).10 
 
Figure 1. Bioactive 4-aminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylates 1a-d.  
Continuing our research in this direction, we decided to explore importance of the 
ester group for the observed biological activities. Therefore, we designed decarboxylated 
analogues, which more closely resemble the adenine structure. Herein, we describe our 
results on the development of an efficient synthesis of new 4-aminopyrazolo[1,5-
a][1,3,5]triazines (5-aza-9-deaza-adenines).   
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2 Results and discussion 
2.1. Attempts to decarboxylate 4-aminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylates 1  
Having alkyl 4-aminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylates 1 prepared earlier,9a we 
initially attempted to involve ethyl 4-aminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (1e) 
into a hydrolytic decarboxylation of the ester group to prepare the corresponding adenine 
analogue 4a.  However, heating 1e in aqueous hydrochloric acid resulted in the formation of 
2 as a product of hydrolytic deamination at the triazine ring, while the ester group remained 
intact (Scheme 1). A similar outcome (formation of 2, 29%) was achieved when hydrochloric 
acid was replaced with sulphuric acid of the same concentration. The peaks of the amino 
group of the starting 1e were replaced in 1H NMR spectrum of 2 by a downfield shifted 
signal of the triazine ring N-H at 13.04 ppm, which together with the carbonyl group peak at 
163.8 ppm in the 13C NMR spectrum, confirmed the structure assignments. The 
ethoxycarbonyl group signals in the NMR spectra of 2 remained present.   
 
Scheme 1. Acid and base-catalysed hydrolytic decomposition of ethyl 4-aminopyrazolo[1,5-
a][1,3,5]triazine-8-carboxylate 1e. 
 
More complex transformations were observed when 1e was treated with alkali 
under similar microwave conditions (Scheme 1). The hydrolysis and decarboxylation of 1e 
were achieved under these conditions, but they were also destructive for the triazine ring 
affording 5-amino-3-phenylaminopyrazole (3a). We concluded that high electrophilicity of 
the triazine ring in 4-aminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylates 1 made them less 
suitable for the initially proposed decarboxylation pathway. However, the isolated 5-amino-
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3-phenylaminopyrazole (3a) appeared to be a suitable substrate for our previously 
developed three-component reaction of aminopyrazoles with cyanamide and orthoformate. 
This reaction could potentially lead to the formation of the desired 4a. Moreover, once 1e 
was effectively converted to 3a, the pyrazole precursor of 1e viz. 5-amino-3-
phenylaminopyrazole-4-carboxylate 5a11 was also explored as a substrate and was 
successfully involved in the hydrolytic decarboxylation under similar conditions.12 Therefore, 
we decided to explore this pathway for the synthesis of adenine analogues 4 (Scheme 2).  
 
 
Scheme 2. Proposed approach for the synthesis of 5-aza-9-deaza-adenines 4. 
 
2.2 Synthesis of 5-aza-9-deaza-adenines 4  
We prepared 3-amino-substituted 5-aminopyrazoles (3)12 and attempted to use them as 
substrates for the one-pot multicomponent reaction (MCR) with cyanamide and triethyl 
orthoformate. Unlike 4-substituted 5-aminopyrazoles, compounds 3 have one more 
nucleophilic centre at C-4, which is additionally activated by two amino groups at the 
neighbouring carbon atoms. This centre increases the complexity of heterocyclizations for 5-
aminopyrazoles in the proposed reaction, potentially resulting in the formation of four 
products 4 and 6-8 (Scheme 3). However, an attempt to carry out this reaction under 
microwave irradiation at 150 °C for 20 min in methanol using 3a as a substrate led to the 
successful formation of the desired 4-amino-7-phenylaminopyrazolo[1,5-a][1,3,5]triazine 
(4a) and no products of the pyrimidine ring annulation (7 and 8) were detected. Their 
structures were excluded on the basis of spectral data, particularly by the presence of 
characteristic H-8 signal at 5.56-6.09 ppm in 1H NMR spectra and HMBC data for 
representative compounds. The X-ray crystallographic data (vide infra) excluded 
regioisomeric structure 6 and unambiguously confirmed formation of compounds 4.   
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Scheme 3. Potential outcomes of the MCR of 3 with triethyl orthoformate and cyanamide.  
The initial attempt of the MCR with 5-amino-3-phenylaminopyrazole (3a), triethyl 
orthoformate and cyanamide afforded 4a in 49% yield (Table 1). Despite the moderate yield, 
product 4a was isolated in pure form without a need of chromatographic purification. 
Further optimising of the reaction conditions, we found that through manipulation with 
reaction time (Table 1, entries 1-3), the yield could be improved to 60% by performing the 
reaction at 150 °C for 25 min (Entry 2). However, conducting the reaction in different 
solvents (Entries 4 and 5) did not increase in yield. Attempts to manipulate with the ratio of 
reagents (Entries 6 and 7) and temperature of reaction (Entries 8 and 9) also did not lead to 
further improvements in the reaction outcome.  
The developed method was optimised using Discover SP (CEM) microwave 
synthesizer and was further tested using another microwave reactor, Monowave 400 
(Anton Paar). The three-component reaction of 3a, triethyl orthoformate and cyanamide 
under the optimized conditions resulted in the formation of 4a in similar yields in the both 
microwave systems (60% and 56%, respectively). To further assess the importance of 
microwave irradiation for the reaction outcome, we also attempted to carry out the MCR of 
3a, triethyl orthoformate and cyanamide in sealed vessels under pressurized, fast, 
conventional heating. The Monowave 50 (Anton Paar) reactor, imitating the heating pattern 
of the earlier optimised microwave irradiation conditions, was found to be suitable for this 
purpose. It led to the successful formation of equally pure 4a was obtained in 53% yield. 
Therefore, we could exclude any significant contribution of non-thermal microwave effects 
in promoting this MCR.  
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Table 1. Optimization conditions for the synthesis of 4-amino-7-phenylaminopyrazolo[1,5-
a][1,3,5]triazine (4a)a 
 
Entry Solvent Ratio of 3a: 
HC(OEt)3 : NCNH2 
Temperature (°C) Time (min) Isolated 
yield (%) 
1 MeOH 1:1.8:1.2 150 20 49 
2 MeOH 1:1.8:1.2 150 25 60 
3 MeOH 1:1.8:1.2 150 30 52 
4 EtOH 1:1.8:1.2 150 25 55 
5 AcOEt 1:1.8:1.2 150 25 21 
6 MeOH 1:2:2 150 25 60 
7 MeOH 1:1.5:1.2 150 25 52 
8 MeOH 1:1.8:1.2 140 25 49 
9 MeOH 1:1.8:1.2 160 25 35 
a The reaction was performed using a Discover SP CEM microwave synthesizer with 1 mmol 
of 5-amino-3-phenylaminopyrazole (3a) in 2 mL of the specified solvent. 
 
With the optimized conditions in hand, the scope of our MCR was explored using 
substrates 3a-l. The one-pot MCR of 5-aminopyrazoles (3a-l), with triethyl orthoformate and 
cyanamide proceeded efficiently with the formation of the desired 4-aminopyrazolo[1,5-
a][1,3,5]triazines 4 in high purity and similar yields (Table 2). The reaction was found to be 
highly chemo- and regioselective affording 1,3,5-triazine ring annulation onto 5-
aminopyrazole 3a-l. No products of reactions involving a potential nucleophilic attack of the 
C-4 pyrazole carbon atom or the secondary amino group were detected. The regioisomeric 
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2-aminopyrazolo[1,5-a][1,3,5]triazines 6 with an alternative position of the primary amino 
group were not found in the reaction mixture.  
 
Table 2. Microwave-assisted synthesis of 8-amino-substituted 5-aza-9-deaza-adenines (4)a 
 
 
 
a The reaction was performed using a Discover SP CEM microwave synthesizer with 1 mmol 
of 5-amino-3-phenylaminopyrazoles (3), 1.8 mmol of triethyl orthoformate and 1.2 mmol of 
cyanamide at 150 °C for 25 min in 2 mL of MeOH.  
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2.3 Restricted rotation around the primary amino group of 5-aza-9-deaza-adenines  
Similarly to the previously reported 5-aza-9-deaza-adenine analogues,9 the primary amino 
group of the prepared compounds 4 was observed to possess a hindered rotation around 
the C-N bond due to the delocalization of electrons over the electron-deficient triazine ring. 
This restricted rotation made the protons on the amino group magnetically non-equivalent 
resulting in the appearance of two broad signals at 7.51 - 8.04 ppm and 8.38 - 8.56 ppm in 
the 1H NMR spectra. The signals were found to coalesce at higher temperature (Fig. 2).  
The dynamic NMR experiments for 4a were performed to assess the restricted 
rotation parameters. The activation enthalpy (H‡) and entropy (S‡) were calculated using 
the rate constant values estimated via the line-shape analysis of the spectra. The H‡ and 
S‡ values calculated using Eyring equation were 3.89 kJ mol-1 and -180.2 J K-1 mol-1, 
respectively.  
 
 
Figure 2. 1H NMR spectra of 4a in DMSO-d6 at range of temperatures.  
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2.4 X-ray crystallography of 4-aminopyrazolo[1,5-a][1,3,5]triazine 4l  
The crystallographic asymmetric unit comprises two independent molecules with the 
molecular structure of first of these shown in Fig. 3(a) and the second in ESI Fig. S2†.  The 
pyrazolo[1,5-a][1,3,5]triazine ring is effectively planar with the r.m.s. deviation for the nine 
fitted atoms being 0.0203 Å [0.0234 Å for the second independent molecule]; the maximum 
deviation from the least-squares plane of 0.0306(14) Å was found for the C8 atom 
[0.0361(14) Å for atom C8a].  The appended primary-N4 and secondary-N7 amine atoms lie 
0.0765(24) and 0.0632(22) Å to either side of the plane [0.0364(25) and 0.0539(22) Å].  With 
a N7‒C71‒C72‒C73 torsion angle of -61.11(2)° [-62.4(2)°], the ethylene group linking the 
amine-N7 and phenyl ring has a ‒syn-clinal conformation.  The major difference between 
the two independent molecules relates to the relative orientation of the pendent aromatic 
residues as seen in the values of the C71‒C72‒C73‒C74 torsion angles of 104.0(2) cf. 
115.8(2)°, Fig. 3(b), nevertheless the dihedral angles between the planes of 88.93(4) cf. 
89.17(4)° are similar and indicate an orthogonal relationship. 
.  
Figure 3. (a) Molecular structure of 4l showing atom labelling scheme and 70% anisotropic 
displacement parameters and (b) an overlay diagram of the two independent molecules 
comprising the asymmetric unit: red image, the molecule shown in (a) and green image, 
molecule “a”.  The molecules are overlapped so that the triazine rings are coincident. 
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As expected from the molecular structure of 4l, there is significant N‒H…N hydrogen 
bonding operating in the crystal; each of the independent molecules engages in analogous 
hydrogen bonding.  Thus, supramolecular ribbons with a corrugated topology are formed 
along the c-axis comprising one type of molecule only, as illustrated for the first 
independent molecule in Fig. 4; the geometric characteristics of the hydrogen bonding are 
given in ESI Table S2†.  The hydrogen bonding involves the primary amine-N4‒H hydrogen 
atoms functioning as the donors to triazine-N3 and pyrazole-N6 as acceptors to form two 
different centrosymmetric synthons, being, respectively, eight-membered {…HNCN}2 and 10-
membered {…HNCN2}2.  The ribbons stack in layers of like-molecules along the a-axis and are 
offset with respect to each (along the b-axis) other allowing their connection into a three-
dimensional architecture via weaker, secondary amine-N7‒H…N1(triazine) hydrogen bonds 
(between unlike molecules).  A view of the unit cell contents for 4l is given in ESI Fig. S3†. 
 
 
Figure 4. Primary amine-N4‒H…N(triazine-N3, pyrazole-N6) hydrogen bonding (see ESI Table 
S2 and Fig. S3†) in the crystal of 4l leading to supramolecular ribbons along the c-axis.  The 
N‒H…N hydrogen bonding is represented as orange dashed lines, and non-participating 
hydrogen atoms have been omitted. 
 
3. Conclusion 
The MCR of 3-amino-substituted 5-aminopyrazoles 3 with cyanamide and triethyl 
orthoformate proceeded smoothly via a selective 1,3,5-triazine ring closure thus generating 
a representative library of new 5-aza-9-deaza-adenines 4. The developed approach is 
practical and robust and could be attractive for organic and medicinal chemists aiming to 
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the preparation of purine-like compounds for the drug discovery process. The method is 
reproducible in different microwave reactors and under microwave-like heating. The 
rotation of the primary amino group in 4 is restricted and activation parameters for this 
process are determined using dynamic NMR spectroscopy.  
 
4. Experimental 
4.1 General information 
Melting points (uncorrected) were determined on a Stuart™ SMP40 automatic melting point 
apparatus. 1H and 13C NMR spectra were recorded on a Bruker Fourier NMR spectrometer 
(300 MHz) using DMSO-d6 as a solvent and TMS as an internal reference. IR spectra were 
recorded in KBr pellets using Varian 640-IR spectrophotometer. Microwave-assisted 
reactions were carried out in the closed vessel focused single mode using a Discover SP 
microwave synthesizer (CEM, USA) monitoring reaction temperature by equipped IR sensor. 
For the method validation, the model reaction was also carried out using Monowave 400 
and Monowave 50 (Anton Paar, Austria) reactors.  
 
4.2 Synthesis of 4-oxo-7-(phenylamino)-3,4-dihydropyrazolo[1,5-a][1,3,5]triazine-8-
carboxylate (2) from 4-aminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (1) 
An ethyl 4-amino-7-phenylaminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (1b, 0.335 
mmol, 100 mg) in aqueous 2M HCl (2.0 mL) was irradiated in a 10 mL seamless pressure vial 
using microwave system operating at maximal microwave power up to 150 W (Discover SP, 
CEM) at 150 °C for 4 min. After cooling, the precipitated product 2 was filtered and washed 
with cold water. An analytical sample was recrystallised from DMF & MeOH. Yield 36%; mp 
329-331 °C (DMF & MeOH); 1H NMR (300 MHz, DMSO-d6): δ 1.33 (3H, t, 3J = 7.1 Hz, CH3), 
4.36 (2H, q, 3J = 7.1 Hz, CH2), 6.98 (1H, t, 3J = 7.4 Hz, H-4′), 7.35 (2H, t, 3J = 8.0 Hz, H-3′ and H-
5′), 7.74 (2H, d, 3J = 7.7 Hz, H-2′ and H-6′), 8.24 (1H, s, H-2), 8.74 (1H, s, NH), 13.04 (1H, br s, 
NH); 13C NMR (75 MHz, DMSO-d6): δ 14.2 (CH3), 60.1 (CH2), 90.6 (C-8), 117.4 (C-2′ and C-6′), 
121.2 (C-4′), 128.9 (C-3′ and C-5′), 140.0 (C-1′), 142.7 (C-8a), 148.7 (C-2), 149.7 (C-4), 154.8 
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(C-7), 163.8 (C=O). Anal. calcd. for C14H13N5O3: C, 56.2; H, 4.4; N, 23.4. Found: C, 55.8; H, 4.5; 
N, 23.2.  
 
4.3 Synthesis of 5-amino-3-phenylaminopyrazole (3a) from ethyl 4-amino-7-
phenylaminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (1b)  
An ethyl 4-amino-7-phenylaminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (1b, 0.335 
mmol, 100 mg) in aqueous 2M NaOH (2.0 mL) was irradiated in a 10 mL seamless pressure 
vial using microwave system operating at maximal microwave power up to 150 W (Discover 
SP, CEM) at 150 °C for 4 min. After cooling, the precipitated product 3a was filtered and 
washed with cold water. An analytical sample was recrystallised from MeOH to give the 
product identical to the one obtained according to the earlier described method.12 Yield 
52%; mp 166-168 °C (MeOH).  
 
4.5 General method for the microwave-assisted synthesis of 5-aza-9-deaza-adenines 4 
A mixture of 3-amino-substituted 5-aminopyrazoles 5 (1.0 mmol), cyanamide (50.4 mg, 1.20 
mmol) and triethyl orthoformate (0.30 mL, 1.8 mmol) in MeOH (2.0 mL) was irradiated in a 
10 mL seamless pressure vial using microwave system operating at maximal microwave 
power up to 150 W (Discover SP, CEM) or 850 W (Monowave 450, Anton Paar) at 150 °C for 
25 min. After cooling, the precipitated product 4 was filtered and washed with cold MeOH 
and recrystallised from a suitable solvent. 
4.5.1 4-Amino-7-(phenylamino)pyrazolo[1,5-a][1,3,5]triazine (4a) 
Yield 60%; mp 277-278 °C (EtOH); 1H NMR (300 MHz, DMSO-d6): δ 5.80 (1H, s, H-8), 6.86 (1H, 
t, 3J = 7.3 Hz, H-4′), 7.26 (2H, t, 3J = 8.0 Hz, H-3′ and H-5′), 7.71 (2H, d, 3J = 7.7 Hz, H-2′ and H-
6′), 7.89 (1H, br s, NH), 7.93 (1H, s, H-2), 8.38 (1H, br s, NH), 9.16 (1H, s, NH); 13C NMR (75 
MHz, DMSO-d6): δ 82.5 (C-8), 116.5 (C-2′ and C-6′), 119.5 (C-4′), 128.7 (C-3′ and C-5′), 141.7 
(C-1′), 148.4 (C-8a), 149.6 (C-4), 154.1 (C-7), 156 (C-2). IR (KBr): ν 3467 (N-H), 3305 (N-H), 
3245 (N-H), 3053 (C-H), 1637, 1557, 1491, 1373, 1267, 906 cm-1. Anal. calcd. for C11H10N6: C, 
58.4; H, 4.5; N, 37.15. Found: C, 58.2; H, 4.6; N, 37.0. 
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4.5.2 4-Amino-7-[(4-fluorophenyl)amino]pyrazolo[1,5-a][1,3,5]triazine (4b) 
Yield 66%; mp 278-280 °C (EtOH); 1H NMR (300 MHz, DMSO-d6): δ 5.78 (1H, s, H-8), 7.07 (2H, 
dd, 3J = 8.9 Hz, 3JHF = 8.9 Hz H-3′ and H-5′), 7.74 (2H, dd, 3J = 9.2 Hz, 4JHF = 4.8 Hz, H-2′ and H-
6′), 7.93 (1H, s, H-2), 7.95 (1H, br s, NH), 8.39 (1H, br s, NH), 9.20 (1H, s, NH); 13C NMR (75 
MHz, DMSO-d6): δ 82.3 (C-8), 115.0 (d, 2JCF = 21.6 Hz, C-3′ and C-5′), 117.8 (d, 3JCF = 7.5 Hz, C-
2′ and C-6′), 138.3 (d, 4 JCF = 2.2 Hz, C-1′), 148.4 (C-8a), 149.6 (C-4), 154.2 (C-7), 156.0 (d, 1JCF 
= 235.8 Hz, C-4′), 156.0 (C-2). IR (KBr): ν 3469 (N-H), 3310 (N-H), 3234 (N-H), 3062 (C-H), 
1685, 1578, 1508, 1372, 1283, 1208 cm-1. Anal. calcd. for C11H9FN6: C, 54.1; H, 3.7; N, 34.4. 
Found: C, 53.9; H, 3.9; N, 34.15. 
4.5.3 4-Amino-7-[(3-chlorophenyl)amino]pyrazolo[1,5-a][1,3,5]triazine (4c) 
Yield 58%; mp 261-263 °C (EtOH); 1H NMR (300 MHz, DMSO-d6): δ 5.82 (1H, s, H-8), 6.88 (1H, 
ddd, 4J = 0.8 Hz, 4J = 2.0 Hz, 3J = 7.9 Hz, H-4′), 7.27 (1H, t, 3J = 8.1 Hz, H-5′), 7.64 (1H, t, 4J = 2.1 
Hz, H-2′), 7.76 (1H, ddd, 4J = 0.8 Hz, 4J = 2.1 Hz, 3J = 8.3 Hz, H-6′), 7.95 (1H, s, H-2), 8.04 (1H, 
br s, NH), 8.42 (1H, br s, NH), 9.39 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): δ 82.8 (C-8), 
115.1 (C-6′), 115.6 (C-2′), 119.2 (C-4′), 130.4 (C-5′), 133.2 (C-3′), 143.1 (C-1′), 148.5 (C-8a), 
149.7 (C-4), 154.2 (C-7), 155.4 (C-2). IR (KBr): ν 3443 (N-H), 3304 (N-H), 3053 (C-H), 1680, 
1619, 1591, 1558, 1447, 1371, 1271 cm-1. Anal. calcd. for C11H9ClN6: C, 50.7; H, 3.5; N, 32.2. 
Found: C, 50.5; H, 3.55; N, 32.1. 
4.5.4 4-Amino-7-[(4-chlorophenyl)amino]pyrazolo[1,5-a][1,3,5]triazine (4d) 
Yield 58%; mp 283-285 °C (EtOH); 1H NMR (300 MHz, DMSO-d6): δ 5.79 (1H, s, H-8), 7.26 (2H, 
d, 3J = 8.9 Hz, H-3′ and H-5′), 7.76 (2H, d, 3J = 9.0 Hz, H-2′ and H-6′), 7.94 (1H, s, H-2), 7.99 
(1H, br s, NH), 8.43 (1H, br s, NH), 9.35 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): δ 82.6 (C-
8), 118.1 (C-2′ and C-6′), 122.9 (C-4′), 128.4 (C-3′ and C-5′), 140.6 (C-1′), 148.4 (C-8a), 149.7 
(C-4), 154.2 (C-7), 155.6 (C-2). IR (KBr): ν 3634 (N-H), 3445 (N-H), 3307 (N-H), 3092 (C-H), 
1680, 1593, 1559, 1443, 1373, 1249 cm-1. Anal. calcd. for C11H9ClN6: C, 50.7; H, 3.5; N, 32.2. 
Found: C, 50.5; H, 3.6; N, 32.0. 
4.5.5 4-Amino-7-[(3-iodophenyl)amino]pyrazolo[1,5-a][1,3,5]triazine (4e) 
Yield 73%; mp 246-248 °C (EtOH); 1H NMR (300 MHz, DMSO-d6): δ 5.81 (1H, s, H-8), 7.06 (1H, 
t, 3J = 8.0 Hz, H-5′), 7.20 (1H, ddd, 4J = 1.0 Hz, 4J = 1.4 Hz, 3J = 7.8 Hz, H-4′), 7.74 (1H, t, 4J = 1.9 
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Hz, H-2′), 7.95 (1H, s, H-2), 7.98 (1H, br s, NH), 8.02 (1H, ddd, 4J = 0.8 Hz, 4J = 2.2 Hz, 3J = 8.3 
Hz, H-6′), 8.41 (1H, br s, NH), 9.29 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): δ 82.8 (C-8), 
94.5 (C-3′), 115.8 (C-6′), 124.2 (C-2′), 128.1 (C-4′), 130.9 (C-5′), 143.2 (C-1′), 148.5 (C-8a), 
149.7 (C-4), 154.2 (C-7), 155.4 (C-2). IR (KBr): ν 3377 (N-H), 3300 (N-H), 3242 (N-H), 3059 (C-
H), 1658, 1544, 1491, 1370, 1275, 1231 cm-1. Anal. calcd. for C11H9IN6: C, 37.5; H, 2.6; N, 
23.9. Found: C, 37.3; H, 2.7; N, 23.7. 
4.5.6 4-Amino-7-[(3-methylphenyl)amino]pyrazolo[1,5-a][1,3,5]triazine (4f) 
Yield 76%; mp 223-225 °C (EtOH); 1H NMR (300 MHz, DMSO-d6): δ 2.31 (3H, s, CH3), 5.79 
(1H, s, H-8), 6.67 (1H, d, 3J = 7.5 Hz, H-4′), 7.14 (1H, t, 3J = 7.8 Hz, H-5′), 7.42 (1H, s, H-2′), 
7.54 (1H, d, 3J = 8.3 Hz, H-6′), 7.88 (1H, br s, NH), 7.92 (1H, s, H-2), 8.38 (1H, br s, NH), 9.06 
(1H, s, NH); 13C NMR (75 MHz, DMSO-d6): δ 21.2 (CH3), 82.6 (C-8), 113.8 (C-6′), 116.9 (C-2′), 
120.4 (C-4′), 128.6 (C-5′), 137.8 (C-3′), 141.6 (C-1′), 148.4 (C-8a), 149.6 (C-4), 154.0 (C-7), 
156.1 (C-2). IR (KBr): ν 3466 (N-H), 3286 (N-H), 3140 (N-H), 3107 (C-H), 1654, 1562, 1499, 
1368, 1327, 1279 cm-1. Anal. calcd. for C12H12N6: C, 60.0; H, 5.0; N, 35.0. Found: C, 59.7; H, 
5.2; N, 34.8.  
4.5.7 4-Amino-7-[(4-methylphenyl)amino]pyrazolo[1,5-a][1,3,5]triazine (4g) 
Yield 65%; mp 270-272 °C (EtOH); 1H NMR (300 MHz, DMSO-d6): δ 2.24 (3H, s, CH3), 5.76 
(1H, s, H-8), 7.06 (2H, d, 3J = 8.1 Hz, H-3′ and H-5′), 7.59 (2H, d, 3J = 8.5 Hz, H-2′ and H-6′), 
7.83 (1H, br s, NH), 7.91 (1H, s, H-2), 8.36 (1H, br s, NH), 9.03 (1H, s, NH); 13C NMR (75 MHz, 
DMSO-d6): δ 20.2 (CH3), 82.3 (C-8), 116.6 (C-2′ and C-6′), 128.1 (C-4′), 129.1 (C-3′ and C-5′), 
139.3 (C-1′), 148.4 (C-8a), 149.6 (C-4), 154.0 (C-7), 156.2 (C-2). IR (KBr): ν 3462 (N-H), 3286 
(N-H), 3029 (C-H), 1659, 1554, 1495, 1372, 1332, 1269 cm-1. Anal. calcd. for C12H12N6: C, 
60.0; H, 5.0; N, 35.0. Found: C, 59.8; H, 5.2; N, 34.8.  
4.5.8 4-Amino-7-[(2-methoxyphenyl)amino]pyrazolo[1,5-a][1,3,5]triazine (4h) 
Yield 75%; mp 225-227 °C (EtOH); 1H NMR (300 MHz, DMSO-d6): δ 3.89 (3H, s, OCH3), 6.09 
(1H, s, H-8), 6.86 (1H, ddd, 4J = 1.8 Hz, 3J = 7.5 Hz, 3J = 7.5 Hz, H-4′), 6.92 (1H, ddd, 4J = 1.8 Hz, 
3J = 7.6 Hz, 3J = 7.6 Hz, H-5′), 6.98 (1H, dd, 4J = 1.7 Hz, 3J = 7.7 Hz, H-6′), 7.00 (1H, s, H-2), 7.91 
(1H, br s, NH), 7.94 (1H, s, NH), 8.36 (1H, br s, NH), 8.55 (1H, dd, 4J = 1.7 Hz, 3J = 7.8 Hz, H-3′); 
13C NMR (75 MHz, DMSO-d6): δ 55.6 (OCH3), 83.7 (C-8), 110.1 (C-3′), 116.9 (C-6′), 119.8 (C-4′) 
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120.8 (C-5′), 130.6 (C-1′), 146.9 (C-2′), 148.1 (C-8a), 149.7 (C-4), 154.0 (C-7), 156.1 (C-2). IR 
(KBr): ν 3427 (N-H), 3331 (N-H), 3050 (C-H), 1672, 1598, 1555 1464, 1373, 1312, 1250 cm-1. 
Anal. calcd. for C12H12N6O: C, 56.2; H, 4.7; N, 32.8. Found: C, 56.0; H, 4.95; N, 32.5. 
4.5.9 4-Amino-7-[(4-methoxyphenyl)amino]pyrazolo[1,5-a][1,3,5]triazine (4i) 
Yield 79%; mp 278-280 °C (EtOH); 1H NMR (300 MHz, DMSO-d6): δ 3.72 (3H, s, OCH3), 5.72 
(1H, s, H-8), 6.85 (2H, d, 3J = 9.0 Hz, H-3′ and H-5′), 7.63 (2H, d, 3J = 9.1 Hz, H-2′ and H-6′), 
7.80 (1H, br s, NH), 7.90 (1H, s, H-2), 8.36 (1H, br s, NH), 8.93 (1H, s, NH); 13C NMR (75 MHz, 
DMSO-d6): δ 55.0 (OCH3), 82.0 (C-8), 114.0 (C-3′ and C-5′), 117.9 (C-2′ and C-6′), 135.3 (C-1′), 
148.4 (C-8a), 149.5 (C-4), 152.8 (C-4′), 154.0 (C-7), 156.3 (C-2). IR (KBr): ν 3467 (N-H), 3243 
(N-H), 3057 (N-H), 3032 (C-H), 1638, 1557, 1493, 1266, 1245, 1034 cm-1. Anal. calcd. for 
C12H12N6O: C, 56.2; H, 4.7; N, 32.8. Found: C, 56.1; H, 4.8; N, 32.7.  
4.5.10 4-Amino-7-[(4-trifluoromethoxyphenyl)amino]pyrazolo[1,5-a][1,3,5]triazine (4j) 
Yield 43%; mp 241-243 °C (EtOH); 1H NMR (300 MHz, DMSO-d6): δ 5.81 (1H, s, H-8), 7.22 (2H, 
d, 3J = 9.0 Hz, H-3′ and H-5′), 7.83 (2H, d, 3J = 9.2 Hz, H-2′ and H-6′), 7.95 (1H, s, H-2), 7.97 
(1H, br s, NH), 8.45 (1H, br s, NH), 9.43 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): δ 82.6 (C-
8), 115.2 (C-2′ and C-6′), 120.2 (q, 1JCF = 254.8 Hz, CF3), 121.6 (C-3′ and C-5′), 140.9 (q, 3JCF = 
1.9 Hz, C-4′), 141.0 (C-1′), 148.4 (C-8a), 149.7 (C-4), 154.2 (C-7), 155.6 (C-2). IR (KBr): ν 3467 
(N-H), 3307 (N-H), 3249 (N-H), 3067 (C-H), 1639, 1561, 1493, 1320, 1268, 1204 cm-1. Anal. 
calcd. for C12H9FN6O: C, 46.5; H, 2.9; N, 27.1. Found: C, 46.3; H, 3.15; N, 26.9.  
 
4.6 Synthesis of 4-amino-7-[(4-isopropylphenyl)amino]pyrazolo[1,5-a][1,3,5]triazine (4k) 
A mixture of 5-amino-3-(4-isopropylphenyl)aminopyrazole 3k (216 mg, 1.00 mmol), 
cyanamide (50.4 mg, 1.20 mmol) and triethyl orthoformate (0.30 mL, 1.8 mmol) in MeOH 
(2.0 mL) was irradiated in a 10 mL seamless pressure vial using microwave system operating 
at maximal microwave power up to 150 W (Discover SP, CEM) at 150 °C for 25 min. Product 
was purified by column chromatography on silica gel using ethyl acetate : hexane (6:4) as an 
eluent. An analytical sample was recrystallised from MeOH.  
Yield 52%; mp 248-250 °C (MeOH); 1H NMR (300 MHz, DMSO-d6): δ 1.19 (6H, d, 3J = 7.0 Hz, 
(CH3)2), 2.83 (1H, m, 3J = 6.9 Hz, CH), 5.77 (1H, s, H-8), 7.12 (2H, d, 3J = 8.5 Hz, H-3′ and H-5′), 
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7.61 (2H, d, 3J = 8.6 Hz, H-2′ and H-6′), 7.80 (1H, br s, NH), 7.91 (1H, s, H-2), 8.35 (1H, br s, 
NH), 9.03 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): δ 24.0 (2 x CH3), 32.6 (CH), 82.4 (C-8), 
116.6 (C-2′ and C-6′), 126.4 (C-3′ and C-5′), 139.4 and 139.6 (C-1′ and C-4′), 148.4 (C-8a), 
149.6 (C-4), 154.0 (C-7), 156.2 (C-2). IR (KBr): ν 3466 (N-H), 3246 (N-H), 3057 (N-H), 2959 (C-
H), 1637, 1552, 1492, 1371, 1267, 1185 cm-1. Anal. calcd. for C14H16N6: C, 62.7; H, 6.0; N, 
31.3. Found: C, 62.5; H, 6.2; N, 31.05.  
 
4.7 Synthesis of 4-amino-7-(phenethylamino)pyrazolo[1,5-a][1,3,5]triazine (4l) 
A mixture of 5-amino-3-phenylethylaminopyrazole 3l (202 mg, 1.00 mmol), cyanamide (50.4 
mg, 1.20 mmol) and triethyl orthoformate (0.30 mL, 1.8 mmol) in MeOH (2.0 mL) was 
irradiated in a 10 mL seamless pressure vial using microwave system operating at maximal 
microwave power up to 150 W (Discover SP, CEM) at 150 °C for 25 min. Product was 
purified by column chromatography on silica gel using ethyl acetate : hexane (6:4) as an 
eluent. Analytical sample was recrystallised from MeCN.  
Yield 62%; mp 166-168 °C (MeCN); 1H NMR (300 MHz, DMSO-d6): δ 1H NMR (300 MHz, 
DMSO-d6): δ 2.88 (2H, t, 3J = 7.5 Hz, CH2), 3.43 (2H, q, 3J = 7.1 Hz, CH2), 5.56 (1H, s, H-8), 6.25 
(1H, t, 3J = 5.8 Hz, NH), 7.17-7.30 (5H, m, H-1′, H-2′, H-3′, H-4′, and H-5′), 7.52 (1H, br s, NH), 
7.83 (1H, s, H-2), 8.10 (1H, br s, NH); 13C NMR (75 MHz, DMSO-d6): δ 35.3 (CH2), 44.4 (CH2), 
80.4 (C-8), 125.9 (C-4′), 128.2 (C-2′ and C-6′), 128.7 (C-3′ and C-5′), 139.8 (C-1′), 149.3 (C-8a 
and C-4), 153.5 (C-7), 160.5 (C-2). IR (KBr): ν 3306 (N-H), 3023 (N-H), 2923 (C-H), 1680, 1564, 
1487, 1379, 1321, 1266, 1009 cm-1. Anal. calcd. for C13H14N6: C, 61.4; H, 5.55; N, 33.05. 
Found: C, 61.2; H, 5.8; N, 32.8.  
 
4.8 Dynamic NMR analysis 
Dynamic NMR experiments and lineshape analysis for 4a were conducted on a Bruker 
Fourier spectrometer (300 MHz) using DMSO-d6 as a solvent and TMS as an internal 
reference at a temperature range of 27 - 60 °C. A temperature below the coalescence point 
(27 °C) was chosen to fix parameters for the dynamic experiments (Fix Line Broadening at 
0.4 Hz). Reaction rate parameters of exchange process at 30 - 60 °C were obtained using the 
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DNMR Lineshape Fitting module13 and plotting a graph of ln(k/T) vs 1/T. The activation 
parameters for the rotation around the C-NH2 bond were calculated using the Eyring 
equation.  
 
4.9 X-ray crystallographic analysis 
Intensity data for crystals (0.03 x 0.09 x 0.13 mm) of 4l were measured at 100 K on an 
Rigaku/Oxford Diffraction XtaLAB Synergy diffractometer (Dualflex, AtlasS2) fitted with 
CuK radiation (λ = 1.54178 Å) so that θmax = 67.1°.  Data reduction and Gaussian absorption 
corrections were by standard methods.14  The structures were solved by direct methods15 
and refined16 on F2 with anisotropic displacement parameters and C-bound H atoms 
included in the riding model approximation.  The N-bound H atoms were refined freely.  A 
weighting scheme of the form w = 1/[2(Fo2) + (aP)2 + bP] where P = (Fo2 + 2Fc2)/3) was 
introduced in each case.  The molecular structure diagrams showing 70% probability 
displacement ellipsoids were generated by ORTEP for Windows17 and the packing diagrams 
with DIAMOND.18 Additional data analysis was made with PLATON.19 
4.9.1 Crystal data for 4l: C13H14N6, M = 254.30, monoclinic, P2/c, a = 21.6171(4), b = 
9.5233(2), c = 12.2819(2) Å,  = 104.881(2)°, V = 2443.63(8) Å3, Z = 8, Dx = 1.382 g cm-3, 
F(000) = 1072,  = 0.725 mm-1, no. reflns meas. = 29918, no. unique reflns = 4377 (Rint = 
0.037), no. reflns with I ≥ 2(I) = 4112, no. parameters = 367, R(obs. data) = 0.048, a and b in 
weighting scheme = 0.057 and 2.237, wR2(all data) = 0.130. CCDC deposition number: 
1866663.  
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